Skip to main content
. Author manuscript; available in PMC: 2025 Aug 28.
Published in final edited form as: Sci Transl Med. 2025 Aug 6;17(810):eads3085. doi: 10.1126/scitranslmed.ads3085

Figure 3. KCL-HO-1i synergizes with chemotherapy to achieve immunological control of tumor growth.

Figure 3

(A) Schematic representing the i.p. dosing strategy for KCL-HO-1i (25 µMol/kg/day) or SnMP (25 µMol/kg/day) and/or 5-FU (40 mg/kg/4 days) or gemcitabine (6.6 mg/kg/7 days) and/or vehicle in MMTV-PyMT mice bearing established tumors (left) and the individual tumor growth curves for the respective treatment (right). (B) Schematic representing the i.p. dosing strategy for non-immune IgG and immune-depleting anti-CD8α antibodies that were also given alongside KCL-HO-1i (25 µMol/kg/day) and gemcitabine (6.6 mg/kg/7 days) and in MMTV-PyMT mice. Vertical dashed black lines mark the start of treatment (day 0) and horizontal red line marks 250 mm3. Solid lines represent individual tumors and mice. Images in panel (A) and (B) were created using BioRender. ** P<0.01.